The purpose of this document is to provide guidance on the application of Health Canada Notice of Compliance (NOC) indications, which are publicly funded, and clarify criteria that were not covered in CADTH’s recommended reimbursement criteria for adult patients being considered for CAR T-cell therapy. This guidance is intended to support standardized use of this therapy in Canada.
This will assist clinicians, policy makers, and payers responsible for treatment and funding decisions. Consensus on the use of CAR T-cell therapy will also support alignment in access between the provinces.
